Clinical Trial

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-06; most recent amendment 2026-04-27.
Status change: Active, Not Recruiting → Recruiting 2026-03-19
Trial Details
NCT Number NCT07325240
Lead Sponsor Mayo Clinic
Collaborators: Alcon Research
Conditions Open Angle Glaucoma, Ocular Hypertension
Enrollment 30 participants
Start Date 2025-11-21
Primary Completion 2027-07 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-01